Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer is a phase 3 interventional study registered as NCT06834672, led by Innovent Biologics (Suzhou), and active but no longer recruiting on the registry. Official title: A Multicenter, Randomised, Open-label Phase III Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Planned enrolment is 450 participants (estimated). The study started in 2025-03-17 and primary completion is expected in 2027-12-28. No results have been posted on ClinicalTrials.gov.